Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
Noosa News20 hours agoWest Coast Eagles draftee Josh Lindsay wants to carry on Troy Selwood’s legacy
-
General21 hours agoLabor to squeeze public service, sparking warnings of job losses
-
Noosa News20 hours agoInsurers scramble after severe storms and hail slam southeast Queensland
-
Noosa News21 hours agoQLS submits key budget requests – Proctor